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Aims Edoxaban is a direct factor Xa inhibitor approved for stroke prevention in atrial fibrillation (AF). Uninterrupted
edoxaban therapy in patients undergoing AF ablation has not been tested.
...................................................................................................................................................................................................
Methods
and results
The ELIMINATE-AF trial, a multinational, multicentre, randomized, open-label, parallel-group study, was conducted
to assess the safety and efficacy of once-daily edoxaban 60 mg (30 mg in patients indicated for dose reduction) vs.
vitamin K antagonists (VKAs) in AF patients undergoing catheter ablation. Patients were randomized 2:1 to edoxa-
ban vs. VKA. The primary endpoint (per-protocol population) was time to first occurrence of all-cause death,
stroke, or International Society of Thrombosis and Haemostasis-defined major bleeding during the period from the
end of the ablation procedure to end of treatment (90 days). Overall, 632 patients were enrolled, 614 randomized,
and 553 received study drug and underwent ablation; 177 subjects underwent brain magnetic resonance imaging to
assess silent cerebral infarcts. The primary endpoint (only major bleeds occurred) was observed in 0.3% (1 patient)
on edoxaban and 2.0% (2 patients) on VKA [hazard ratio (95% confidence interval): 0.16 (0.02–1.73)]. In the abla-
tion population (modified intent-to-treat population including patients with ablation), the primary endpoint was
observed in 2.7% of edoxaban (N= 10) and 1.7% of VKA patients (N= 3) between start of ablation and end of
treatment. There were one ischaemic and one haemorrhagic stroke, both in patients on edoxaban. Cerebral micro-
emboli were detected in 13.8% (16) patients who received edoxaban and 9.6% (5) patients in the VKA group
(nominal P= 0.62).
...................................................................................................................................................................................................
Conclusion Uninterrupted edoxaban therapy represents an alternative to uninterrupted VKA treatment in patients undergoing
AF ablation.
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Introduction
Catheter ablation is a safe and effective strategy for rhythm control in
patients with symptomatic atrial fibrillation (AF). The most important
peri-procedural complications comprise stroke, transient ischaemic
attack (TIA), and cardiac tamponade. To reduce the risk of thrombo-
embolic events, systemic anticoagulation before, during, and after abla-
tion is mandatory.1,2 In addition to the intraoperative administration of
heparin to maintain the activated clotting time (ACT) >300 s, uninter-
rupted therapy with warfarin is recommended. This strategy is associ-
ated with a lower risk of bleeding compared to temporary vitamin K
antagonist (VKA) discontinuation covered by a bridging strategy with
low-molecular-weight heparin.3 Although non-vitamin K antagonist
oral anticoagulants (NOACs) have been demonstrated to have super-
ior efficacy and similar (dabigatran, rivaroxaban) or lower (apixaban,
edoxaban) risk of bleeding in the long-term treatment of patients with
AF compared with VKAs,4 there has been a lack of data to support
their uninterrupted peri-procedural use during AF ablation. Recently,
three studies comparing uninterrupted rivaroxaban, dabigatran, and
apixaban to VKA showed similarly low rates of bleeding associated
with uninterrupted NOAC vs. uninterrupted VKA therapy.5–7 These
results led to the guideline recommendation to continue uninterrupt-
ed treatment with NOACs during and after catheter ablation for
patients who were previously receiving these NOACs.1
In the ENGAGE AF-TIMI 48 trial,8 once-daily treatment with edoxa-
ban 60/30 mg regimens was non-inferior compared with well-managed
warfarin for the prevention of stroke or systemic embolism but with su-
perior safety, however, experience in ablation was very limited.9 Since
there has been no randomized controlled trial on the use of edoxaban
for catheter ablation of AF, the ELIMINATE-AF trial [a Prospective,
Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE)
Parallel Group Study Comparing Edoxaban vs. VKA in Subjects
Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation], was
conducted to investigate the efficacy and safety of uninterrupted
edoxaban vs. VKA in patients undergoing catheter ablation for AF.
Patients and methods
Trial design
ELIMINATE-AF (ClinicalTrials.gov: NCT02942576) was a multi-
national, multicentre, randomized, open-label, parallel-group,
blinded-endpoint evaluation (PROBE) study, the design and rationale
of which has been previously published in detail.10 The study was
conducted between March 2017 and September 2018 in accordance
with the Declaration of Helsinki, the International Conference on
Harmonisation Good Clinical Practice guidelines, and local regula-
tions on clinical research. The protocol was approved by the institu-
tional review board or independent ethics committee at each
participating study centre. All patients provided written informed
consent prior to enrolment. An independent Data and Safety
Monitoring Board reviewed the safety data during the conduct of the
trial to protect patient rights, safety, and well-being.
Trial population
Adult patients (>_18 years of age) with documented non-valvular AF
(paroxysmal, <_7 days; persistent, >7 days but <_12 months; long-
standing persistent, >12 months) scheduled for their first or repeated
catheter ablation for AF were eligible. Full inclusion and exclusion cri-
teria can be found in the design paper.10 Patients scheduled for cath-
eter ablation with energy sources other than radiofrequency or
cryoballoon were excluded from participating, as were patients with
mechanical heart valves, moderate to severe mitral stenosis, transient
AF or AF of a reversible nature, and patients who had a bioprosthetic
heart valve implanted within 3 months prior to randomization.
Treatments
Patients were centrally randomized in a 2:1 ratio to receive edoxaban
or VKA using a block randomization method. Patients randomized to
edoxaban received once-daily edoxaban 60 mg (30 mg if they met
one or more of the criteria for dose reduction).10 The preferred
VKA varied across countries (phenprocoumon in Germany and
Belgium, acenocoumarol in Spain, and warfarin in Belgium and in all
other countries). Patients randomized to a VKA were required to
maintain an international normalized ratio (INR) of 2.0–3.0 at least
for the last 10 days prior to ablation. International normalized ratio
values were documented at least once a week during the pre-
ablation period and once a month during the post-ablation period.
Patients with INR between 1.5 and 3.5 at the last measurement be-
fore the ablation procedure could still undergo ablation at the discre-
tion of the investigator. During the study period, including on the day
before the procedure, patients randomized to once-daily edoxaban
took their scheduled dose in the evening.
Pre-ablation anticoagulant treatment was mandated for 21–
28 days according to current guidelines.1,11 Transoesophageal
echocardiography or intracardiac echocardiography was performed
prior to ablation to identify cardiac clots. If clots were identified, abla-
tion was not performed, and patients were switched to standard of
care and entered the 30-day follow-up period. The maximum interval
between the last pre-ablation edoxaban dose and the ablation
procedure was 18 h in order to maintain sufficient inhibition of en-
dogenous factor Xa.
During ablation, unfractionated heparin (UFH) was used according
to European Heart Rhythm Association guidelines11 targeting an
ACT of 300–400 s. Study medication was restarted at least 6 h post-
sheath removal after achieving adequate haemostasis. Treatment
continued for 90 days post-ablation. Clinical visits occurred at 30, 60,
and 90 days post-ablation. Patients discontinued study medication at
end of treatment and were transitioned to an oral anticoagulant at
the investigator’s discretion.
Magnetic resonance imaging sub-study
A magnetic resonance imaging (MRI) sub-study was performed to
detect silent cerebral lesions. An MRI examination of the head was
conducted either at 1.5 Tesla (T) or at 3 T field strength within
4 ± 2 days after ablation. The following MRI sequences were used: a
T1-weighted spin echo sequence to rule out acute cerebral haemor-
rhage, diffusion-weighted imaging (DWI), and (post-processed) ap-
parent diffusion coefficient maps to assess acute cerebral infarction,
as well as a fluid-attenuated inversion recovery (FLAIR) sequence to
differentiate acute from chronic ischaemic brain lesions (sequence
parameters given in Supplementary material online, Table S1). FLAIR
images were also assessed for the burden of white matter hyper-
intensities usually attributed to chronic small vessel disease according
2 S.H. Hohnloser et al.
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to the Fazekas scale.12 The Fazekas scale is the most widely used scale
for quantifying periventricular and deep white matter disease severity
on T2-weighted images.12
Images failing the immediate quality check were repeated when-
ever feasible. All images were independently evaluated by two expe-
rienced neuroradiologists who were blinded to treatment allocation.
Trial endpoints
The primary study endpoint was time to first occurrence of all-cause
death, stroke (ischaemic, haemorrhagic, or undetermined), or
International Society of Thrombosis and Haemostasis-defined major
bleeding during the period from the end of the ablation procedure to
end of treatment (90 days). The primary safety endpoint was the time
to the first occurrence of International Society on Thrombosis and
Haemostasis (ISTH)-defined major bleeding from the date of the first
intake of study medication to end of treatment.
Secondary efficacy endpoints included a variety of other compos-
ite and individual thromboembolic events, and secondary safety end-
points included other bleeding events.10 All clinical events were
centrally adjudicated by a committee of experts blinded as to patient
treatment allocation.
Trial size and statistical analysis
ELIMINATE-AF was an exploratory study aiming at enrolment of ap-
proximately 560 patients to document about 450 patients who
underwent ablation and had no major protocol violation [per-proto-
col (PP) analysis set]. This sample size was considered appropriate by
the steering committee to generate clinically meaningful data. The
sample size necessary to establish formal non-inferiority between
edoxaban and VKA would have made the trial unfeasible.
The pre-specified main analysis for the primary outcome para-
meter and key secondary efficacy parameters was defined by the PP
analysis set and the ‘post-ablation period’ (end of the ablation proced-
ure to day 90/end of treatment visit), and for the primary and key sec-
ondary safety parameters based on the modified intent-to-treat
(mITT) analysis set and the ‘overall period’ (date of first intake of study
medication to the day 90/end of treatment). The mITT analysis set
consisted of all randomized patients who received at least one dose
of study medication (safety analysis set). To allow for a comparison
of our study results with other NOAC ablation trials,5–7 an analysis
period from the start of ablation to the day 90/end-of-treatment visit
was also evaluated (ablation population).
Based on adjudicated events, the number and percentage of
patients experiencing specific events were summarized by treatment
group. Results of a time-to-first event analysis using a Cox propor-
tional hazard model are presented as hazard ratios (HRs) including 2-
sided 95% confidence intervals (CIs) and nominal P-values. Due to
the exploratory nature of the study, all P-values should be inter-
preted in an exploratory, non-confirmatory way.
Descriptive statistics for continuous and categorical variables were
summarized as means (standard deviation), median (lower–upper
quartile), and numbers (percentages), respectively.
The safety analysis set was used to summarize treatment emergent
adverse events (TEAE) defined as adverse events which started on or
after first dose of the study medication or started prior to but then
worsened after the first dose of the assigned study medication.
Results
Patient population
A total of 632 patients were enrolled at 58 sites across 11 countries
in Europe, Asia, and Canada. Of these, 614 patients were randomized
and 602 received at least one dose of study medication (mITT popu-
lation). A total of 553 subjects received study drug and underwent
catheter ablation (ablation population). The PP population consisted
of 417 patients (Figure 1). Reasons for exclusion from the PP popula-
tion are given in Supplementary material online, Table S2.
Baseline characteristics were well balanced between treatment
groups (intent-to-treat population, Table 1, and PP population,
Supplementary material online, Table S3). Edoxaban adherence was
calculated on the basis of number of tablets taken (mean > 97%) and
VKA adherence was measured by monitoring the INR and calculating
the time in therapeutic range (TTR).13 The median TTR in the con-
trol group was 65% (mITT) and 73% (PP). Time in therapeutic range
was 84% (mITT) and 91% (PP) when an extended INR range of 1.8–
3.2 was applied. The majority of patients with ablation (96.4%)
received trial medication until the end of treatment/day 90.
Peri-procedural heparin use
The study protocol called for peri-procedural administration of UFH
to maintain the ACT >300 s which was achieved in 66.7% of cases.
During the ablation procedure, patients assigned to edoxaban
received on average 14.261 IU of UFH compared to 11.473 IU in the
VKA arm (nominal P< 0.0001) (Table 2). Administration of UFH
resulted in an average ACT of 303 s in the edoxaban and 338 s in the
VKA arm (nominal P< 0.0001).
Primary endpoint and its components
The incidence of the primary endpoint (death, stroke, or ISTH-
defined major bleeding during the post-ablation period) was 0.3% (1
patient) in the edoxaban group and 2.0% (2 patients) in the VKA
group [HR (95% CI): 0.16 (0.02–1.73), Table 3]. All three events were
major bleedings. Including all events that occurred from the start of
the ablation procedure to the end of treatment in the PP population,
the primary composite endpoint was observed in 1.3% (4 patients) in
the edoxaban and in 3.0% (3 patients) in the VKA group [HR (95%
CI): 0.42 (0.10–1.89)]. In the ablation population, the primary end-
point was observed in 2.7% (10 edoxaban patients) and 1.7% (3 VKA
patients) from the start of the ablation procedure to end of treat-
ment (Table 3).
The primary safety endpoint (ISTH-defined major bleeding) in the
mITT population and overall study period was observed in 2.5% (10
patients) in the edoxaban group and 1.5% (3 patients) in the VKA
group (Table 4).
Specifically, the type and number of bleeding events in the edoxa-
ban vs. the VKA group were the following: pericardial tamponade
requiring drainage 3 vs. 2; bleeding at puncture site 3 vs. 1; intracranial
bleeding 1 vs. 0; gastrointestinal bleeding 2 vs. 0; and other bleedings
1 vs. 0 (Table 4).
During the overall study period (mITT), there were one ischaemic
and one haemorrhagic stroke, both in patients assigned to edoxaban.
The ischaemic stroke occurred in a 50-year-old male patient on day 4
after ablation. This patient with a history of heart failure and reduced
Uninterrupted edoxaban vs. VKAs for AF ablation 3
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.left ventricular ejection fraction was overweight (144 kg), had supra-
normal creatinine clearance and was inappropriately dose-reduced
to edoxaban 30 mg. The haemorrhagic stroke occurred in a 71-year-
old male with a body weight of 71 kg (creatinine clearance of 86 ml/
min, and apart from hypertension, no additional risk factors) prior to
ablation on study day 17. This patient received edoxaban 60 mg, as
no dose reduction criterion were present.
Other types of bleeding
Clinically relevant non-major (CRNM) bleeding events occurred in
7.9% (32 patients) in the edoxaban and in 3.6% (7 patients) in the
VKA group. There were no CRNM bleeding events during ablation in
either treatment group. The majority of CRNM bleeding events
occurred during the first days after ablation.
Magnetic resonance imaging sub-study
An MRI of the head was acquired in 177 of 207 (85.5%) eligible
patients across 14 centres participating in the MRI sub-study. Non-
diagnostic image quality led to the exclusion of 2 of 177 patients.
Patients who participated in the sub-study showed similar baseline
characteristics as those who did not. There were 168 (116 edoxaban,
52 VKA) analysable MRIs of good diagnostic image quality for T1 and
DWI and 173 (118 edoxaban, 55 VKA) for FLAIR sequencing. Acute
cerebral microembolism <_10 mm size (Figure 2) was detected in
13.8% (16) of patients (95% CI 7.52–20.07%) who received edoxa-
ban, and 9.6% (5) of patients (95% CI 1.60–17.63%) in the VKA group
(nominal P= 0.62). The distribution of lesions between treatment
groups was very similar. An acute left cerebellar embolism of
20 15 mm in diameter was observed in a clinically asymptomatic
patient receiving edoxaban. The burden of subcortical and deep
white matter hyperintensities according to the Fazekas scale was well
balanced between MRI sub-study treatment groups (Supplementary
material online, Table S4).
Treatment emerging adverse events
The number of patients with TEAEs was balanced between study
arms with 51.9% (N= 210) and 50.3% (N= 99) in the edoxaban and
the VKA groups, respectively.
The number of serious TEAEs was low and also comparable
among groups with 9.9% (N= 40) in the edoxaban and 7.6% (N= 15)
in the VKA group. Severe TEAEs occurred in 2.2% (N= 9) and 2.5%
(N= 5) in the edoxaban and the VKA groups, respectively
(Supplementary material online, Table S5).
Discussion
The observations made in ELIMINATE-AF show that uninterrupted
administration of edoxaban represents an alternative to continuous
anticoagulation with VKA in patients undergoing catheter ablation of
AF. The management of anticoagulation around ablation is much eas-
ier with edoxaban as there is no need for regular INR controls. The
incidence of the composite primary endpoint (death, stroke, and
ISTH major bleeding) in the main analysis was low [1 vs. 2 events; HR
(95% CI): 0.16 (0.02–1.73)]. International Society on Thrombosis and
Haemostasis-defined major bleeding events (primary safety end-
point) in the overall study period were also low with 2.5% in the
edoxaban group compared to 1.5% in patients assigned to VKA.
There was no statistically significant difference in the incidence of
major bleedings between edoxaban and VKA. This event rate for
edoxaban 60 mg QD is similar to those observed with dabigatran
150 mg BID in the RE-CIRCUIT trial (1.6%) and with apixaban 5 mg
BID in the AXAFA trial (3.1%) (all bleeding rates according to ISTH
definition; Figure 3).5,7 In contrast, bleeding rates observed in the VKA
Figure 1 CONSORT diagram. ITT, intent-to-treat; mITT, modified intent-to-treat; PP, per-protocol; VKA, vitamin K antagonist.
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Table 1 Patient demographics (intent-to-treat analysis set, N5 614)
Total (N5614) Edoxaban (N5 411) VKAa (N5203)
Age (years) 60.5 (53–67) 60.0 (53–67) 61.0 (52–67)
Male gender, n (%) 439 (71.5) 290 (70.6) 149 (73.4)
BMI (kg/m2) 28.1 (25.4–31.2) 28.1 (25.1–31.1) 27.8 (25.7–31.2)
CHA2DS2-VASc score, n (%)
0 140 (22.8) 96 (23.4) 44 (21.7)
1 166 (27.0) 109 (26.5) 57 (28.1)
>_2 308 (50.2) 206 (50.1) 102 (50.2)
Medical history, n (%)
Congestive heart failure 110 (17.9) 71 (17.3) 39 (19.2)
Previous CAD (prior MI, prior PCI, or prior CABG) 117 (19.2) 76 (18.6) 41 (20.3)
Previous MI 24 (3.9) 19 (4.6) 5 (2.5)
Previous stroke/TIAb 30 (4.9) 22 (5.4) 8 (3.9)
PAD 10 (1.6) 7 (1.7) 3 (1.5)
Diabetes mellitus 87 (14.2) 55 (13.4) 32 (15.8)
Hypertension 371 (60.4) 250 (60.8) 121 (59.6)
Mild valvular heart disease 52 (8.5) 32 (7.8) 20 (9.9)
Creatinine clearance (mL/min) 96.5 (79.1–118.3) 95.8 (77.6–117.6) 97.2 (79.9–118.7)
AF type, n (%)
Paroxysmal 415 (67.6) 284 (69.1) 131 (64.5)
Persistent 166 (27.0) 105 (25.5) 61 (30.0)
Long-standing persistent 33 (5.4) 22 (5.4) 11 (5.4)
Previous cardioversion, n (%) 310 (50.5) 209 (50.9) 101 (49.8)
ECG at randomization, n (%)
AF 148 (24.5) 98 (24.3) 50 (25.0)
Atrial flutter 28 (4.6) 18 (4.5) 10 (5.9)
TOE/ICE (ablation population5mITTwith ablation analysis set)c (N5 553) (N5 375) (N5178)
TOE 393 (74.6) 266 (74.3) 127 (75.1)
Intracardiac echocardiography 134 (25.4) 92 (25.7) 42 (24.9)
Last dose of study anticoagulant to start of ablation procedure (h) 15.4 (13.5–17.1) 14.8 (13.3–16.5) 16.5 (14.8–19.5)
Sheath removal to next dose of study anticoagulant (h) 6.7 (6.1–8.0) 6.7 (6.1–8.0) 6.6 (6.1–7.9)
Medication use at baseline, n (%)
VKA 242 (39.4) 146 (35.5) 96 (47.3)
Amiodarone 156 (25.9) 97 (24) 59 (29.9)
Other antiarrhythmic drugs 419 (69.6) 278 (68.6) 141 (71.6)
Digitalis glycosides 30 (5.0) 22 (5.4) 8 (4.0)
Betablocker 455 (75.6) 312 (77) 142 (72.6)
Calcium channel antagonists 136 (22.6) 90 (22.2) 46 (23.4)
ACE or angiotensin receptor inhibitors 303 (50.3) 201 (49.6) 102 (51.8)
Diuretics 153 (25.4) 100 (24.7) 53 (26.9)
Aspirin 13 (3.2) 7 (1.7) 6 (3.0)
Clopidogrel 10 (1.7) 7 (1.7) 3 (1.5)
Proton-pump inhibitors 267 (44.4) 184 (45.4) 83 (42.1)
NSAIDs 30 (5.0) 24 (5.9) 6 (3.0)
Data are presented as median (Q1–Q3) unless otherwise indicated.
a86% of the patients on VKA received warfarin.
bIncludes ischaemic, embolic, and undetermined; haemorrhagic stroke prohibited.
cIn total, 5 patients with detected thrombus (edoxaban 3; VKA 2); none of these underwent ablation procedure.
ACE, angiotensin converting enzyme; AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHA2DS2-VASc,
Congestive heart failure, Hypertension, Age >_75, Diabetes mellitus, prior Stroke or transient ischaemic attack or thromboembolism, Vascular disease, Age 60–70, female Sex
category; ECG, electrocardiography; ICE, intracardiac echocardiography; ITT, intent-to-treat; MI, myocardial infarction; mITT, modified intent-to-treat; NSAID, non-steroidal
anti-inflammatory drugs; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack; TOE, transoesophageal echocardiography;
VKA, vitamin K antagonist.
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Table 2 Use of unfractionated heparin and activated clotting time during catheter ablation (modified intent-to-treat
with ablation population)
Total (N5553) Edoxaban (N5 375) VKA (N5 178) P-value
Total dose of UFH (IU)
Mean (SD) 13 362 (5945) 14 261 (6397) 11 473 (4300) <0.0001
Median 12 301 13 000 10 225
Q1–Q3 10 000–16 000 10 000–17 500 8541–14 000
Mean ACT (s)
Mean (SD) 314.2 (51.45) 302.8 (41.64) 338.0 (61.15) <0.0001
Median 307.7 301.4 332.6
Q1–Q3 281.6–341.5 277.0–330.4 300.5–371.0
P-values are exploratory.
ACT, activated clotting time; SD, standard deviation; UFH, unfractionated heparin; VKA, vitamin K antagonist.
....................................................................................................................................................................................................................
Table 3 Primary study endpoint [composite of all-cause death, stroke, and major bleeding (International Society on
Thrombosis and Haemostasis)] in the per-protocol and the modified intent-to-treat population
Edoxaban (ITT N5 411) VKA (ITT N5 203) HR (95% CI)
PP population post-ablationa
N 316 101
Primary endpoint events, n (%) 1 (0.3) 2 (2.0) 0.16 (0.02–1.73)
PP population peri- and post-ablationb
N 316 101
Primary endpoint events, n (%) 4 (1.3) 3 (3.0) 0.42 (0.10–1.89)
mITT population peri- and post-ablationb
N 375 178
Primary endpoint events, n (%) 10 (2.7) 3 (1.7) 1.60 (0.44–5.78)
aFrom the end of catheter ablation to day 90/end of treatment.
bFrom the start of catheter ablation to day 90/end of treatment.
CI, confidence interval; HR, hazard ratio; mITT, modified intent-to-treat; PP, per-protocol; VKA, vitamin K antagonist.
...............................................................
........................ ........................
.............................................................
....................................................................................................................................................................................................................
Table 4 Primary safety endpoint: major bleeding events and study periods (safety set, modified intent-to-treat
population)
Study period Major bleeding events
Edoxaban
(N5 405), n (%)
VKA
(N5 197), n (%)
Edoxaban vs. VKA HR (95% CI)
Overall events 10 (2.5) 3 (1.5) 1.68 (0.46–6.07)
n (%) n (%) Diagnosisa
Edoxaban/VKA (n/n)
Pre-ablation period (day of randomization
to start of ablation procedure)
1 (0.3) 0 (0.0) Haemorrhagic stroke
Peri-ablation period (from sheath insertion
to sheath removal)
4 (1.0) 1 (0.5) Cardiac tamponade 1/1
Bleeding at puncture site 2/0
Lower GI bleeding 1/0
Post-ablation period
<_48 h after ablation
>48 h after ablation to end of treatment
3 (0.7)
2 (0.5)
2 (1.0)
0 (0.0)
Cardiac tamponade 2/1b
Bleeding at puncture site 1/1b
Menstrual bleeding 1b/0
Lower GI bleeding 1/0
aAblation procedure-related events given in italics.
bEvents also included in the per-protocol analysis set.
CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; VKA, vitamin K antagonist.
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Figure 2 Examples of acute cerebral microembolism after atrial fibrillation ablation in the magnetic resonance imaging sub-study. Acute cerebral
microembolism are depicted by diffusion-weighted imaging (white arrows in A, C, E, G) with corresponding demarcation on fluid-attenuated inversion
recovery images (white arrows in B, D, F, H) suggesting an appearance over 24 h ago. (A and B) A larger clinically asymptomatic left cerebellar embol-
ism in an asymptomatic patient randomized to edoxaban. The fluid-attenuated inversion recovery images also revealed chronic white matter hyperin-
tensities (black arrow in H). DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery.
Figure 3 Incidence rates of combined primary endpoint in ELIMINATE-AF (death, stroke, and International Society on Thrombosis and
Haemostasis-defined major bleeding) in the non-vitamin K oral anticoagulant and vitamin K antagonist arms in the modified intent-to-treat peri- and
post-ablation study period. Comparison with combined event rates in the three other randomized trials comparing uninterrupted non-vitamin K oral
anticoagulant therapy with uninterrupted vitamin K antagonist therapy are shown. For all trials, rates of International Society on Thrombosis and
Haemostasis-defined major bleeding events were included. AF, atrial fibrillation; APX, apixaban; DABI, dabigatran; EDX, edoxaban; ISTH,
International Society on Thrombosis and Haemostasis; NOAC, non-vitamin K oral anticoagulant; RIV, rivaroxaban; VKA, vitamin K antagonist.
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arms of the three studies varied considerably, ranging between 1.7%
in our study, 4.4% in AXAFA, and 6.9% in RE-CIRCUIT.5,7 Of note,
the incidence of the most feared bleeding complication, cardiac tam-
ponade, was similar in the edoxaban group (0.7%) and in the VKA
group (1.0%). Importantly, patients in the VKA arm of our study had
excellent INR control with a TTR of 65% or even 84% in the
extended TTR range of 1.8–3.2. It is possible that the major bleeding
rate differences in the VKA groups among these four studies report-
ing TTR between 65% and 84% represent a by-chance finding or
were due to differences in patient populations and in different VKAs
used (short- vs. long-acting VKA). Whereas there were no statistical-
ly significant differences in the incidence of major bleedings between
edoxaban and VKA in our study, there was a trend towards higher
CRNM bleeding events in the edoxaban arm. Not unexpectedly,
most of the bleeding events occurred during the ablation procedure
or in the first 48 h after completion. Hence, it is tempting to speculate
that this may be in part related to the cumulative dose of intra-
procedural heparin. Comparable to apixaban in the AXAFA trial,7
the mean ACT achieved during ablation was significantly lower in the
edoxaban than in the VKA arm. As a consequence, investigators may
have been inclined to administer a higher dose of UFH in patients
assigned to edoxaban (on average, 24% more heparin than in the
VKA arm). Other studies comparing factor Xa inhibitors with VKA
have also reported use of higher heparin dosages in NOAC com-
pared with VKA patients.6,14 It can be speculated that the higher dose
of heparin may have contributed to an increased likelihood of bleed-
ing events (e.g. from the vascular access sites) in the edoxaban group.
This observation carries important clinical implications regarding sur-
veillance of patients during the post-ablation period.
In ELIMINATE-AF, two patients suffered from stroke, one ischae-
mic and the other haemorrhagic (incidence 0.36%), both in patients
receiving edoxaban. This stroke incidence is comparable to those
observed in other studies. Specifically, in the AXAFA study, two
strokes occurred in 633 patients (0.3%), one stroke in VENTURE AF
among 248 patients (incidence 0.4%), and one TIA in RE-CIRCUIT
among 635 patients (0.2%; Figure 3).5–7 As in RE-CIRCUIT,5 none of
the patients enrolled in our study died. These findings from the four
uninterrupted NOAC vs. VKA randomized studies indicate that the
risk of thromboembolic events is low and is similar to those reported
in retrospective registry studies.15
With the exception of AXAFA,7 the present study is the only
one which systematically used MRI for detection of silent brain
lesions. Asymptomatic cerebral infarcts have been described in
patients undergoing AF ablation at incidences of 2% up to 41% of sub-
jects.16–18 Our MRI sub-study revealed similar rates of acute cerebral
microemboli (13.8% vs. 9.6%) after catheter ablation under edoxaban
compared to VKA. The higher incidence of microemboli described in
the AXAFA study7 is likely due to different timing of image acquisi-
tion. In contrast to the AXAFA study, in which a brain MRI was per-
formed within 48 h after the ablation procedure,7 the MRIs in our
study were acquired 4 ± 2 days after ablation, which is why the cere-
bral microemboli were already demarcated on the FLAIR images.16,19
Considering the very low incidence of ischaemic stroke and silent
cerebral ischaemic lesions in our study population, it is likely that
not only thromboembolism but also procedure-related air
microembolizations may have contributed to the detected cerebral
lesions on DWI.
As with previous trials examining rivaroxaban, dabigatran, and
apixaban in the context of catheter ablation, ELIMINATE-AF has the
limitation of not being a formal non-inferiority trial of edoxaban vs.
VKA. However, such a trial was deemed not to be affordable given
the need to enrol at least 3000 patients for a non-inferiority margin
of 1.38 and a power of 80%. Like the other studies examining uninter-
rupted NOAC therapy for AF ablation, the present study is therefore
an exploratory evaluation of the safety and efficacy of edoxaban in
patients undergoing catheter ablation of AF. Another limitation con-
sists of the exclusion of a considerable proportion of patients from
the PP analysis due to predefined protocol violation criteria, including
time out of INR range. This resulted in a relatively uneven exclusion
of patients in the VKA vs. the edoxaban treatment groups. Finally,
ELIMINATE-AF (like the other three NOAC ablation studies) is an
unblinded study, which may allow for some residual bias.
In conclusion, results from ELIMINATE-AF demonstrate that
edoxaban represents an alternative to VKA in this clinical scenario.
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Supplementary material is available at European Heart Journal online.
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